Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

Astrazeneca (AZN) closed the latest trading day at $70.25, indicating a +0.95% change from the previous session's end. This move outpaced the S&P 500's daily loss of 0.47%. Meanwhile, the Dow ...

(RTTNews) - The U.S. Food and Drug Administration has approved AstraZeneca Plc ... the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given a consensus recommendation of “Buy” by the ten research firms ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

AstraZeneca (NASDAQ:AZN), a global pharmaceutical firm, has announced a C$820 million (US$570 million) investment in Canada, ...

(RTTNews) - British drug maker AstraZeneca Plc (AZN.L ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...